CURIS INC (CRIS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, CURIS INC's filing signal continuing negative.

Curis, Inc. is a clinical-stage biopharmaceutical company focused on the development of emavusertib (CA-4948), an orally available small molecule inhibitor targeting IRAK4 and FLT3. The company is currently evaluating emavusertib in Phase 1/2 and Phase 2 studies for relapsed/refractory primary central nervous system lymphoma (PCNSL) and chronic lymphocytic leukemia (CLL), respectively, often in combination with other therapies. Emavusertib has received Orphan Drug Designation from the FDA for PCNSL, AML, and MDS, and from the European Commission for PCNSL. Curis has a collaboration and exclusive license agreement with Aurigene Discovery Technologies Limited for emavusertib and other programs. The company has incurred substantial losses since inception and expects to continue doing so, relying on external financing to fund its operations and development programs.

Curis's primary revenue driver has historically been royalty payments from the sale of Erivedge, a product developed under a collaboration with Genentech. However, following the sale of its Erivedge assets in November 2025, the company is no longer entitled to these revenues.